The problems with delay discounting: a critical review of current practices and clinical applications.

Allen J Bailey, Ricardo J Romeu, Peter R Finn
Author Information
  1. Allen J Bailey: Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA. ORCID
  2. Ricardo J Romeu: Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.
  3. Peter R Finn: Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.

Abstract

Delay discounting paradigms have gained widespread popularity across clinical research. Given the prevalence in the field, researchers have set lofty expectations for the importance of delay discounting as a key transdiagnostic process and a 'core' process underlying specific domains of dysfunction (e.g. addiction). We believe delay discounting has been prematurely reified as, in and of itself, a core process underlying psychological dysfunction, despite significant concerns with the construct validity of discounting rates. Specifically, high delay discounting rates are only modestly related to measures of psychological dysfunction and therefore are not 'core' to these more complex behavioral problems. Furthermore, discounting rates do not appear to be specifically related to any disorder(s) or dimension(s) of psychopathology. This raises fundamental concerns about the utility of discounting, if the measure is only loosely associated with most forms of psychopathology. This stands in striking contrast to claims that discounting can serve as a 'marker' for specific disorders, despite never demonstrating adequate sensitivity or specificity for any disorder that we are aware of. Finally, empirical evidence does not support the generalizability of discounting rates to other decisions made either in the lab or in the real-world, and therefore discounting rates cannot and should not serve as a summary measure of an individual's decision-making patterns. We provide recommendations for improving future delay discounting research, but also strongly encourage researchers to consider whether the empirical evidence supports the field's hyper-focus on discounting.

Keywords

References

  1. Front Psychol. 2015 Mar 26;6:328 [PMID: 25859234]
  2. J Dual Diagn. 2009 Apr 1;5(2):131-138 [PMID: 20182654]
  3. J Abnorm Psychol. 2017 May;126(4):454-477 [PMID: 28333488]
  4. J Exp Anal Behav. 2017 May;107(3):388-401 [PMID: 28467023]
  5. Pharmacol Ther. 2012 Jun;134(3):287-97 [PMID: 22387232]
  6. Clin Psychol Sci. 2014 Mar;2(2):119-137 [PMID: 25360393]
  7. Nebr Symp Motiv. 2017;64:227-267 [PMID: 30351565]
  8. JAMA Psychiatry. 2019 Nov 1;76(11):1176-1186 [PMID: 31461131]
  9. Curr Dir Psychol Sci. 2012 Feb;21(1):8-14 [PMID: 22773897]
  10. Trends Mol Med. 2018 Feb;24(2):121-128 [PMID: 29307501]
  11. J Exp Psychol Gen. 2014 Aug;143(4):1489-514 [PMID: 24635188]
  12. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Jul;1(4):316-325 [PMID: 27722208]
  13. Clin Psychol Sci. 2015 Mar 1;3(2):202-214 [PMID: 25893146]
  14. Am J Psychiatry. 2010 Jul;167(7):748-51 [PMID: 20595427]
  15. Biol Psychiatry. 2011 Feb 1;69(3):260-5 [PMID: 20965498]
  16. Trends Neurosci. 2015 Jun;38(6):345-52 [PMID: 25959611]
  17. Exp Clin Psychopharmacol. 2018 Feb;26(1):94-107 [PMID: 29389172]
  18. Behav Processes. 2011 May;87(1):1-9 [PMID: 21385637]
  19. J Exp Psychol Learn Mem Cogn. 2013 Mar;39(2):573-88 [PMID: 22866891]
  20. Psychopharmacology (Berl). 2016 Sep;233(18):3361-70 [PMID: 27449350]
  21. Alcohol Clin Exp Res. 2016 Jul;40(7):1558-66 [PMID: 27246691]
  22. Exp Clin Psychopharmacol. 2006 Aug;14(3):318-28 [PMID: 16893275]
  23. J Gen Psychol. 2011 Jan-Mar;138(1):35-48 [PMID: 21404948]
  24. Front Psychol. 2015 Sep 01;6:1104 [PMID: 26388788]
  25. Addiction. 2013 Mar;108(3):506-15 [PMID: 23033972]
  26. Proc Biol Sci. 2004 May 7;271 Suppl 4:S177-9 [PMID: 15252976]
  27. Alcohol Clin Exp Res. 2002 Feb;26(2):272-9 [PMID: 11964568]
  28. Decision (Wash D C ). 2020 Jul;7(3):212-224 [PMID: 34621906]
  29. J Behav Med. 2017 Oct;40(5):832-838 [PMID: 28508382]
  30. Exp Clin Psychopharmacol. 2020 Jun;28(3):276-290 [PMID: 31424235]
  31. J Exp Psychol Gen. 2018 Sep;147(9):1349-1381 [PMID: 30148386]
  32. Psychopharmacology (Berl). 2011 Aug;216(3):305-21 [PMID: 21373791]
  33. Psychol Addict Behav. 2018 Mar;32(2):197-204 [PMID: 29355332]
  34. Behav Res Methods. 2016 Dec;48(4):1608-1620 [PMID: 26542975]
  35. Addiction. 2017 Jan;112(1):51-62 [PMID: 27450931]
  36. Psychol Addict Behav. 2020 Feb;34(1):175-181 [PMID: 31219266]
  37. Appetite. 2018 Oct 1;129:155-161 [PMID: 29959952]
  38. Front Psychol. 2016 Jan 13;6:1948 [PMID: 26793131]
  39. J Gen Psychol. 2010 Jul-Sep;137(3):273-86 [PMID: 20718227]
  40. Exp Clin Psychopharmacol. 2014 Jun;22(3):222-8 [PMID: 24708144]
  41. Alcohol Clin Exp Res. 2018 Dec;42(12):2432-2441 [PMID: 30247753]
  42. Alcohol Clin Exp Res. 2017 Sep;41(9):1622-1629 [PMID: 28743164]
  43. Psychol Assess. 2000 Mar;12(1):102-11 [PMID: 10752369]
  44. Neuropharmacology. 2014 Jan;76 Pt B:518-27 [PMID: 23806805]
  45. Psychol Bull. 1955 Jul;52(4):281-302 [PMID: 13245896]
  46. Exp Clin Psychopharmacol. 2009 Feb;17(1):51-61 [PMID: 19186934]
  47. Psychon Bull Rev. 2021 Apr;28(2):686-694 [PMID: 33219456]
  48. Exp Clin Psychopharmacol. 2008 Jun;16(3):264-74 [PMID: 18540786]
  49. Alcohol Clin Exp Res. 2021 May;45(5):1100-1108 [PMID: 33742491]
  50. Psychol Methods. 2021 Feb;26(1):18-37 [PMID: 32134313]
  51. Psychol Assess. 2016 Oct;28(10):1198-1206 [PMID: 26595217]
  52. Exp Clin Psychopharmacol. 2022 Feb;30(1):59-72 [PMID: 33001696]
  53. Psychol Med. 2019 Jan;49(2):190-199 [PMID: 30070191]
  54. Psychol Bull. 2014 Mar;140(2):374-408 [PMID: 24099400]
  55. Curr Opin Psychol. 2019 Dec;30:59-64 [PMID: 30852411]
  56. J Exp Anal Behav. 2015 Jan;103(1):218-33 [PMID: 25556903]
  57. Drug Alcohol Depend. 2009 Aug 1;103(3):99-106 [PMID: 19443136]
  58. Addiction. 2013 Nov;108(11):1916-23 [PMID: 23795646]
  59. PLoS One. 2012;7(11):e47225 [PMID: 23226198]

Grants

  1. T32 DA024628/NIDA NIH HHS
  2. R01 AA013650/NIAAA NIH HHS
  3. T32 MH103213/NIMH NIH HHS

MeSH Term

Behavior, Addictive
Decision Making
Delay Discounting
Humans
Impulsive Behavior
Psychopathology
Reward

Word Cloud

Created with Highcharts 10.0.0discountingdelayratesprocessdysfunctionclinicalresearchresearcherstransdiagnostic'core'underlyingspecificpsychologicaldespiteconcernsconstructvalidityrelatedthereforebehavioralproblemsdisorderspsychopathologymeasureserveempiricalevidencedecision-makingDelayparadigmsgainedwidespreadpopularityacrossGivenprevalencefieldsetloftyexpectationsimportancekeydomainsegaddictionbelieveprematurelyreifiedcoresignificantSpecificallyhighmodestlymeasurescomplexFurthermoreappearspecificallydimensionraisesfundamentalutilitylooselyassociatedformsstandsstrikingcontrastclaimscan'marker'disordersneverdemonstratingadequatesensitivityspecificityawareFinallysupportgeneralizabilitydecisionsmadeeitherlabreal-worldsummaryindividual'spatternsproviderecommendationsimprovingfuturealsostronglyencourageconsiderwhethersupportsfield'shyper-focusdiscounting:criticalreviewcurrentpracticesapplicationsAlcoholRDoCeconomicsimpulsivitysubstanceuse

Similar Articles

Cited By